Prosecution Insights
Last updated: April 19, 2026

Immunitybio Inc.

9 pending office actions

Portfolio Summary

9
Total Pending OAs
3
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19277274 COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS DUFFY, BRADLEY 1643 Non-Final OA Jul 22, 2025
19211886 CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS ZAIDI, SYED A 2432 Non-Final OA May 19, 2025
18897262 Methods And Systems For Producing A Protein Of Interest In A Plant WILLIAMS, KEITH RICHARD 1663 Final Rejection Sep 26, 2024
18437185 GENERATING CIK NKT CELLS FROM CORD BLOOD BELYAVSKYI, MICHAIL A 1644 Final Rejection Feb 08, 2024
18225098 COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION ANDERSON-FEARS, KEENAN NEIL 1687 Non-Final OA Jul 21, 2023
18345670 METHODS FOR STIMULATING PROLIFERATION OR DIFFERENTIATION OF AN IMMUNE CELL WITH A MULTI-CHAIN CHIMERIC POLYPEPTIDE LOCKARD, JON MCCLELLAND 1647 Non-Final OA Jun 30, 2023
18195588 CD16high CD57high NK-92MI Cells DAHLE, CHUN WU 1641 Final Rejection May 10, 2023
17767615 Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples LIN, JERRY 1685 Non-Final OA Apr 08, 2022
17115360 Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection REDDIG, PETER J 1646 Non-Final OA Dec 08, 2020

Managing Immunitybio Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month